Search
Flunarizine
go.drugbank.com/drugs/DB04841ApprovedInvestigationalIt is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. … Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
Synonyms: 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazineProducts: NATIL N 5MG, NATIL N 10MGAmmonia N-13
go.drugbank.com/drugs/DB09326ApprovedAmmonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease
Synonyms: Ammonia N 13, Ammonia N-13Products: Ammonia N 13 N 13, Ammonia N 13Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[L12123] It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. … [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalThe Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Phenolphthalein
go.drugbank.com/drugs/DB04824ApprovedWithdrawnPhenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.
Categories: Compounds used in a research, industrial, or household settingCoagulation factor VIIa Recombinant Human
go.drugbank.com/drugs/DB00036ApprovedInvestigationalNovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Categories: Increased Coagulation Factor IX ActivityDorocubicel
go.drugbank.com/drugs/DB19448Approved[L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.
Luspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigational[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin
Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions
Categories: Corticosteroids, Moderately Potent (Group II)